MoneyWorks4Me

Cipla informs about financial results

30 Oct 2025 Evaluate
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that the Board of Directors of the Company at its meeting held today i.e., 30th October, 2025, has approved the unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September, 2025. They are enclosed as follows: (1) Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards for the quarter and half year ended 30th September, 2025; and (2) Limited review report (standalone and consolidated) issued by Walker Chandiok & Co. LLP, Statutory Auditor of the Company for the quarter and half year ended 30th September, 2025. The Board meeting of the Company which commenced today at 09:30 am (IST) and is still in progress. The end time of the meeting will be separately intimated to the Stock Exchanges on conclusion. The above-mentioned documents will also be available on the Company’s website www.cipla.com in the Investors Section.  

The above information is a part of company’s filings submitted to BSE. 
Peers
Company Name CMP
Sun Pharma. Inds. 1844.45
Dr. Reddys Labs. 1225.00
Cipla 1390.00
Lupin 2071.70
Zydus Lifesciences 1216.10
View more..